Your session is about to expire
← Back to Search
Empagliflozin 25 MG + Liraglutide 1.8 MG for Type 2 Diabetes (NATRIURETIC Trial)
NATRIURETIC Trial Summary
This trial studies how two diabetes treatments affect heart health in people with type 2 diabetes without heart failure.
- Type 2 Diabetes
NATRIURETIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NATRIURETIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of a condition called gastroparesis, where your stomach takes longer than usual to empty its contents.You have a history of not being able to sense when your blood sugar levels are too low.You have a known intolerance or negative reaction to SGLT2i or GLP-1RA medications.Your body weight is within a certain range, called Body Mass Index (BMI), which goes from 18.5 to 40.0 kg/m2.You have recently had a heart condition like a heart attack, heart procedure, or surgery.You had weight loss surgery or other surgeries that affect how your body absorbs nutrients within the past year.You have been taking weight loss medication or following a strict diet for the past three months, and your weight has been changing a lot during that time.You are currently taking corticosteroid medications.You have had pancreatitis in the past.You or your family has a history of a specific type of thyroid cancer called medullary thyroid cancer or a condition called MEN2B.
- Group 1: Liraglutide
- Group 2: Empagliflozin
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment currently admitting participants?
"The information on clinicaltrials.gov confirms that this medical trial is not currently enrolling patients. Initially posted on January 24th 2019, it was last updated September 1st 2020 and no longer seeks participants; however, 2261 other studies are still actively recruiting at the moment."
To what medical conditions is Empagliflozin 25 MG + Liraglutide 1.8 MG prescribed?
"Empagliflozin 25 MG + Liraglutide 1.8MG is frequently utilized for hospitalizations, but can also be used therapeutically to combat diet-related issues, inadequate control when relying upon a single medication treatment plan, and cardiovascular diseases."
To what extent does the combination of Empagliflozin 25 MG + Liraglutide 1.8 MG pose a risk to patients?
"Due to the lack of clinical data that has been gathered on efficacy, Empagliflozin 25 MG + Liraglutide 1.8 MG was given a rating of 2 for safety based on our team's assessment at Power."
To what capacity is this investigation accommodating participants?
"At this time, recruitment for the trial is closed. The initial posting was on January 24th 2019 and the most recent update occurred in September 2020. If searching for other studies with a similar diagnosis, 2187 trials are currently recruiting patients diagnosed with type 2 diabetes, while 74 clinical trials are seeking participants to test Empagliflozin 25 MG + Liraglutide 1.8 MG as an intervention."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger